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Axon degeneration is widespread both in neurode-
generative disease and in normal neural develop-
ment, but the molecular pathways regulating these
degenerative processes and the extent to which
they are distinct or overlapping remain incompletely
understood. We report that calpastatin, an inhibitor
of calcium-activated proteases of the calpain family,
functions as a key endogenous regulator of axon
degeneration. Calpastatin depletion was observed
in degenerating axons after physical injury, and
maintaining calpastatin inhibited degeneration of
transected axons in vitro and in the optic nerve
in vivo. Calpastatin depletion also occurred in a cas-
pase-dependent manner in trophic factor-deprived
sensory axons and was required for this in vitro
model of developmental degeneration. In vivo, cal-
pastatin regulated the normal pruning of retinal gan-
glion cell axons in their target field. These findings
identify calpastatin as a key checkpoint for axonal
survival after injury and during development, and
demonstrate downstream convergence of these
distinct pathways of axon degeneration.
INTRODUCTION
Axon degeneration is characterized by elimination of axons
or their branches, and results in loss of connectivity between
neuronal cell bodies and their innervating targets. Axon degener-
ation has become increasingly appreciated as a critical feature of
many neurological disorders including traumatic injury, Alz-
heimer’s disease, Parkinson’s disease, multiple sclerosis, and
amyotrophic lateral sclerosis (Burke and O’Malley, 2012; Cole-
man, 2005; De Vos et al., 2008; Johnson et al., 2012; Wang
et al., 2012). Damage to axons often precedes the onset of
symptoms and neuronal cell death, further supporting the clinical
relevance of axon degeneration in the progression of those dis-Norders. The functional preservation of axons is therefore thought
to be an important therapeutic target for treatment of neurode-
generative disease.
An extensively studied model of axonal death is Wallerian
degeneration. Following physical damage to a nerve, axon seg-
ments distal to the lesion site undergo a stereotyped form of
self-destruction (Waller, 1850) characterized by loss of the action
potential, destruction of the cytoskeleton, membrane frag-
mentation, and demyelination (Coleman, 2005; Coleman and
Freeman, 2010). The discovery of the Wallerian Degeneration
Slow (Wlds) mouse (Lunn et al., 1989), and the subsequent char-
acterization of the Wlds fusion protein, whose gain-of-function
delays Wallerian degeneration of distal axon segments for an
extended period (Mack et al., 2001), demonstrated that the
demise of injured axons is not triggered simply by loss of nutritive
support from the neuronal cell body, but is instead regulated by
an intrinsic mechanism in axons (Coleman, 2005; Coleman and
Freeman, 2010). In support of this notion, we and our colleagues
have recently shown that loss-of-function of the endogenous
gene Sarm1 also significantly delays Wallerian degeneration in
mice, with a protective effect that is comparable to that observed
in the Wlds mutant (Osterloh et al., 2012). Despite these ad-
vances, the full molecular cascade underlying Wallerian degen-
eration remains to be elucidated.
Axon degeneration is not unique to neurodegenerative disor-
ders, but is also widely observed as a normal feature of the
development of nervous systems (Luo and O’Leary, 2005). The
selective elimination of exuberant axons is crucial for the precise
wiring of neural circuits. A classic example of axon degeneration
in the developing nervous system is observed in the mammalian
retinotectal system. During development, the axons of temporal
retinal ganglion cells initially overshoot their future termination
zone in the superior colliculus. Later, axon segments distal to
the termination zone are stereotypically pruned through local
degeneration (Feldheim and O’Leary, 2010). Studies in the past
decade have revealed a variety of molecular signals responsible
for eliciting axon pruning in different contexts, including activa-
tion of Semaphorin-Plexin or Eph-Ephrin signals. More recently,
a critical role of the classic apoptotic pathway in developmental
axon degeneration has begun to emerge. A signaling cascade
involving the proapoptotic effector BAX and downstreameuron 80, 1175–1189, December 4, 2013 ª2013 Elsevier Inc. 1175
Figure 1. Depletion of Axonal Calpastatin during Injury-Induced Degeneration
(A and B) Enrichment of axonal proteins from neuronal cultures. Cultures of DRG explants (A) or dissociated DRG neurons (B) were set up, and their neuronal cell
bodies were removed. Axons were visualized by immunostaining; asterisks denote the regions of neuronal cell bodies before the removal.
(C) Protein samples prepared from 5,000 dissociated DRG neurons, or their cell body fraction and axonal fraction, were subjected to immunoblot analysis.
(legend continued on next page)
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Regulation of Axon Degeneration by Calpastatincaspases, including caspase-9, caspase-3, and caspase-6, is
essential for axonal death in in vitro models of pruning triggered
by trophic-factor deprivation, and contributes to axon degener-
ation in the developing retinotectal system (Nikolaev et al., 2009;
Simon et al., 2012; Vohra et al., 2010).
Interestingly, Wallerian degeneration appears independent of
the apoptotic degeneration pathway (Simon et al., 2012; Vohra
et al., 2010; Whitmore et al., 2003), and conversely, expression
of Wlds protein or genetic knockout of Sarm1 is ineffective in
delaying developmental axon degeneration in mouse or fruitfly
(Hoopfer et al., 2006; Osterloh et al., 2012). Thus, whether diver-
gent signaling pathways in pathological or developmental axon
degeneration share particular regulatory step(s) remains unclear.
Calpains areCa2+-activated cysteine proteases implicated in a
variety of physiological processes,whoseaberrant activation can
also result in proteolysis of vital cellular components (Goll et al.,
2003; Liu et al., 2004). In mammals, the most well-characterized
members of the calpain family are calpain-1 (m-calpain) and cal-
pain-2 (m-calpain), which are ubiquitously expressed in tissues,
including the peripheral and central nervous systems (Croall
andDeMartino, 1991;Goll et al., 2003).Calpain activity is critically
controlled not only by intracellular Ca2+, but also by the endoge-
nous proteinaceous inhibitor calpastatin (Croall and DeMartino,
1991; Goll et al., 2003). Calpastatin binds and inhibits calpains
via its calpain-inhibitor domains when the proteases are acti-
vated byCa2+ (Hanna et al., 2008). Importantly, persistent activity
of calpains can result in destruction of calpastatin, which has led
to the notion that calpastatin is a ‘‘suicide inhibitor,’’ ensuring that
calpains are kept in check in the case of transient fluctuations of
intracellular Ca2+ and only reach their full proteolytic potential
in the prolonged presence of the cation (Blomgren et al., 1999;
Nakamura et al., 1989). Therefore, the cellular content and distri-
bution of calpastatin, as well as its balance with calpain activity,
are key determinants of how efficiently Ca2+-activated calpains
are inhibited (Goll et al., 2003; Hanna et al., 2008).
Previous studies have linked the overactivation of calpains
to neurodegenerative disorders (Arau´jo and Carvalho, 2005;
Camins et al., 2006; Liu et al., 2004). Calpains have also long
been implicated in axon degeneration triggered by physical
injury in vitro (George et al., 1995), and recently exogenous trans-
genic expression of calpastatin was used to provide definitive
evidence for calpain involvement in sciatic and optic nerve
degeneration after transection in vivo (Ma et al., 2013). Endo-
geous calpastatin has been proposed to play prosurvival roles(D–F) Depletion of axonal calpastatin during degeneration of injured axons. Repre
axotomy are shown (D). The percentage of degenerated axons was quantified (E
subjected to immunoblot analysis (F).
(G) Direct proteolysis of calpastatin by calpains. Recombinant mouse calpastatin
protein purity was assessed by silver staining (left panel). Two hundred fifty nanog
calpain-2 in the presence of 5 mM Ca2+ at 37C for 30 min, and then subjected
(H and I) Inhibition of calpains but not the proteasome preserved calpastatin in ax
for 1 hr prior to axotomy. One microgram of axonal protein harvested at the indi
(J) Wlds/Nmnat1 functions upstream of calpastatin depletion. DRG neurons w
described in the Supplemental Experimental Procedures. Onemicrogram of axona
immunoblot analysis.
(K) Calpastatin depletion occurs downstream of Sarm1. 0.5 mg of axonal protein h
after axotomy was subjected to immunoblot analysis.
See also Figure S1.
Nin adult neurons under degenerative conditions, including in
models of ischemia-excitotoxicity (Bano et al., 2005; D’Orsi
et al., 2012; Rao et al., 2008; Takano et al., 2005; Vosler et al.,
2011) and MPTP/6-hydroxydopamine-induced parkinsonism
(Crocker et al., 2003; Grant et al., 2009). However, whether
endogenous calpastatin exerts any role in regulating survival
specifically of axons in neurodegeneration models has not
been determined. Moreover, involvement of calpastatin and cal-
pains in other types of axon degeneration, e.g., in developmental
pruning, remains unexplored.
We report that calpastatin is depleted rapidly in the injured
axons of cultured neurons as well as in transected nerves,
concomitant with full-scale activation of calpains and axonal
death. Axons with a reduction of endogenous calpastatin un-
dergo accelerated Wallerian degeneration, whereas, consistent
with recent results (Ma et al., 2013), maintaining the protein’s
level protects injured axons both in neuronal cultures and in vivo.
Interestingly, the calpastatin-calpain system is also involved in
axon degeneration during development. Occurring downstream
of the caspase cascade, depletion of calpastatin, followed by
calpain activation, is required for the death of nerve growth factor
(NGF)-deprived sensory axons in vitro. Furthermore, calpastatin
critically regulates developmental pruning of retinal ganglion cell
axons in vivo. These results provide evidence that calpastatin
functions as an endogenous determinant of axonal survival
both after injury and during development, and that distinct path-
ways of axon degeneration converge on this checkpoint prior to
dismantling the axons.
RESULTS
Enrichment of an Axonal Fraction from Neuronal
Cultures
To study molecular mechanisms underlying axon degeneration,
we optimized an approach allowing efficient enrichment of the
axonal fraction for biochemical analysis, from either explant cul-
tures or dissociated neuron cultures. With 40,6-diamidino-2-phe-
nylindole (DAPI) staining, >99% of neuronal cell bodies could be
reliably removed by this procedure (Figures 1A and 1B). To
confirm separation of cell body contents from the axonal frac-
tion, we compared the distribution of several cellular markers
(Figure 1C). Cytoskeleton components (microtubules, neurofila-
ments, and actin filaments) were relatively evenly distributed
among the cell body and axonal fractions, but the nuclearsentative phase-contrast images of axons at the indicated time points following
), mean ± SEM; 1 mg of axonal protein harvested at the same time points were
was purified as described in the Supplemental Experimental Procedures, and
rams calpastatin protein was incubated with increasing amounts of calpain-1 or
to immunoblot analysis.
otomized axons. DRG explants were treated with the small-molecule inhibitors
cated time points were subjected to immunoblot analysis.
ere transduced by lentivirus overexpressing GFP control or cyto-Nmnat1 as
l protein harvested at the indicated time points postaxotomywere subjected to
arvested from Sarm1+/ or Sarm1/ SCG neurons at the indicated time points
euron 80, 1175–1189, December 4, 2013 ª2013 Elsevier Inc. 1177
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Regulation of Axon Degeneration by Calpastatinproteins lamin-A/C and histone H3 were effectively excluded
from the axonal fraction. This approach therefore enabled us to
focus on molecular events occurring specifically in axons during
degeneration. As well, while the in vitro experiments in the cur-
rent study are largely based on mouse embryonic dorsal root
ganglion (DRG) sensory neurons, this axon/neurite-enriching
approach is also applicable to other neurons, including embry-
onic cortical neurons, embryonic motor neurons, and superior
cervical ganglion neurons (data not shown), and thus represents
a valuable tool for investigating axon degeneration in a variety of
neuronal types.
Calpastatin Regulates the Survival of Physically Injured
Axons
Toexplore critical regulatorsof axondegeneration,wefirst useda
well-studied in vitro model of Wallerian degeneration (Figures 1D
and 1E). Embryonic day 12.5 (E12.5) to E13.5 DRG explants were
cultured with NGF. Upon separation from their cell bodies, axons
remained intact for the first 4 hr, although all their growth cones
collapsed (data not shown; Sasaki and Milbrandt, 2010). Signs
of degeneration, including blebbing and fragmentation along
axons, became evident around 6 hr postaxotomy, and the vast
majority of axons degenerated at 8–10 hr postaxotomy (Figures
1D and 1E). We carried out biochemical analysis of axonal frac-
tions prepared during this degenerative process to examine
candidate proteins previously implicated in neuronal cell death.
Anabruptdecreaseof thecalpastatin level in axonswasobserved
after axotomy at the 6 hr and later time points but not before
(Figure 1F). Interestingly, this change of calpastatin level tempo-
rally correlated with the morphological degeneration of axons
(Figure 1E), as well as the calpain-mediated degradation of neu-
rofilaments, specifically neurofilament-M, neurofilament-L, and
a-internexin/NF-66 (Figure 1F, and see below), consistent with a
role for calpastatin in axon degeneration. Calpastatin appeared
as doublet bands around 110 kDa, likely reflecting isoforms with
different sites of transcription initiation (Goll et al., 2003).
Of note, levels of a-tubulin and b-tubulin protein monomers
appeared unchanged during the degeneration of injured axons
(Figure 1F; data not shown), providing a useful control for
normalization of protein samples, even though polymerized
axonal microtubules, visualized by TUJ1 immunostaining, were
disassembled (Figures S1D and S2C available online; data not
shown; Zhai et al., 2003). Moreover, themajority of the candidate
proteins we examined also remained largely intact through the
degenerative process, including proteins involved in the
apoptotic pathway (BAX and caspase-3), Wallerian degenera-
tion (DLK), trophic signaling (PI3K-p110a, MEK1/2, and ERK1/
2), cytoskeletal dynamics (b-actin and Rac1/2/3) and meta-
bolism (Hexokinase-I and GAPDH; Figure 1F). Thus, the degen-
eration of injured axons does not involve nonspecific degrada-
tion of axosolic proteins, and the degradation of calpastatin
and other select proteins is a specific response to injury.
Calpastatin functions as a ‘‘suicide inhibitor’’ for calpains to
keep the proteases in check when they are transiently activated
by intracellular calcium; however, when calcium levels increase
persistently, calpains can eventually proteolyze calpastatin to
overcome its inhibitory effect (Blomgren et al., 1999; Nakamura
et al., 1989). Indeed, we observed in an in vitro biochemical1178 Neuron 80, 1175–1189, December 4, 2013 ª2013 Elsevier Inc.assay that calpastatin was readily degraded by both calpain-1
and calpain-2 (Figure 1G). Because calpain activity has been
implicated in axon degeneration triggered by physical injury
in vitro (George et al., 1995), the destruction of calpastatin that
we observed could be due to activated calpains in axons. How-
ever, degradation of calpastatin has also been suggested to be
mediated by the proteasome (Mellgren, 1997). To distinguish
these possibilities, we inhibited the two types of proteases with
small-molecule inhibitors. As a precaution, we compared three
commonly used calpain inhibitors, ALLN, z-Val-Phe-CHO (cal-
pain inhibitor-III), and MG-132, with two specific proteasome
inhibitors, lactacystin and epoxomicin. ALLN, calpain inhibitor-
III, and MG-132 showed comparable inhibitory activity toward
calpain-1 and calpain-2, while lactacystin and epoxomicin had
no effect (Figure S1A). However, treatment with ALLN, MG-
132, lactacystin, or epoxomicin all resulted in the accumulation
of polyubiquitinated proteins in axons, reflecting their inhibition
of proteasome activity (Figure S1B). Therefore, among the three
common calpain inhibitors, calpain inhibitor-III appeared rela-
tively specific to calpains, whereas ALLN and MG-132 inhibited
both calpains and the proteasome. When axotomized axons
were treated with calpain inhibitor-III, it preserved the protein
level of calpastatin, as well as inhibiting proteolysis of neurofila-
ments (Figure 1H). The observation that calpain inhibitor-III did
not completely inhibit calpastatin depletion might be explained
by the high binding affinity (low nanomolar range) of calpastatin
toward calpains (Goll et al., 2003). The depletion of calpastatin
after axotomy was also blocked in the presence of the Ca2+-
chelator EGTA (Figure 1I). In contrast, proteasome inhibition by
lactacystin or epoxomicin had no effect on the calpastatin level
(Figure 1H). Together, these results suggested that calpastatin
is degraded in injured axons by calpains.
Previous studies have shown that the Wlds mutant protein can
significantly delay the degeneration of injured axons in mice
(Mack et al., 2001). We compared the calpastatin level in axo-
tomized axons overexpressing GFP (as a control) or a cytosolic
version of Nmnat1(R125A/R127A; cyto-Nmnat1), which has
been shown to be functionally equivalent to the protective Wlds
fusion protein (Sasaki et al., 2009). While calpastatin was rapidly
degraded in control axons, depletion was completely blocked in
the presence of cyto-Nmnat1 for at least 24 hr (Figure 1J), sup-
porting the view that Wlds/Nmnat1 inhibits an upstream step
leading to calpastatin depletion. In addition, we examined deple-
tion of calpastatin in Sarm1/ axons, which are also protected
againstWallerian degeneration (Osterloh et al., 2012). Compared
to the axons of Sarm1+/ SCG neurons, the protein was signifi-
cantly preserved in injuredSarm1/ axons (Figure 1K), suggest-
ing that calpastatin depletion occurs downstream of the Sarm1-
dependent degeneration signal. Interestingly, we observed that
the previously documented depletion of axonal Nmnat2 or
SCG10 after axotomy (Gilley and Coleman, 2010; Shin et al.,
2012) was not prevented by cyto-Nmnat1 overexpression or
Sarm1-knockout (Figure S1C; data not shown). Thus, there is
not a necessary correlation between protection against Waller-
ian degeneration and maintenance of axonal proteins. The pres-
ervation of calpastatin therefore reflects a specific effect of Wlds/
Nmnat1 expression or Sarm1 deletion, and fits with calpastatin
being an integral component of the degeneration mechanism.
Figure 2. Calpastatin Regulates Axonal Survival after Injury
(A and B) Overexpression of calpastatin in axons. DRG neurons were subjected to lentiviral transduction, and exogenously-expressed calpastatin in axons was
detected by immunostaining (A). Onemicrogram of axonal protein harvested fromGFP- or calpastatin-expressing neurons was subjected to immunoblot analysis
(B). Asterisk denotes a nonspecific band cross-reacting with the calpain-1 large subunit antibody.
(C and D) Axonal calpastatin inhibited injury-induced degeneration. GFP- or calpastatin-expressing DRG neurons were treated with DMSO or 20 mM calpain
inhibitor-III for 1 hr prior to axotomy. Representative phase-contrast images of axotomized axons at the indicated time points are shown (C). The percentage of
degenerated axons was quantified (D), mean ± SEM, *p < 0.01.
(E) Calpastatin functions as a suicide-inhibitor. One microgram of axonal protein harvested from GFP- or calpastatin-expressing neurons at the indicated time
points postaxotomy was subjected to immunoblot analysis.
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Regulation of Axon Degeneration by CalpastatinAs an aside, in the course of these experiments, we observed
that, consistent with previous reports (MacInnis and Campenot,
2005; Zhai et al., 2003), inhibition of proteasome activity in the
axons of SCG (sympathetic) neurons led to a significant delay
of degeneration upon axotomy (Figures S1D and S1E). However,
treatment of axotomizedDRG (sensory) axonswith lactacystin or
epoxomicin showed no effect on neurofilament proteolysis (Fig-
ure 1H) or axon degeneration (Figure S2C) following axotomy.
Similarly, the proteasome inhibitors failed to block the injury-
induced degeneration of embryonic motor neuron axons, or
either pre- or postcrossing spinal commissural axons (data not
shown), suggesting that the previously reported involvement ofNthe proteasome in Wallerian degeneration is not universal but
rather neuronal-type dependent.
Given the temporal correlation between the depletion of
axonal calpastatin and the degeneration of physically injured
axons, it appeared plausible that calpastatin could function as
a checkpoint for axonal survival. We therefore tested whether
an increase of the calpastatin level can enhance its capacity to
protect injured axons against degeneration. DRG neurons were
transducedwith lentivirus expressing calpastatin, which resulted
in a significant increase of the protein’s level in both cell bodies
and axons compared to neurons transduced with a control lenti-
virus expressing GFP (Figure 2A). The transduction rate undereuron 80, 1175–1189, December 4, 2013 ª2013 Elsevier Inc. 1179
(legend on next page)
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Regulation of Axon Degeneration by Calpastatinour culture conditions was over 95% across experiments (data
not shown). Immunoblot analysis of axonal fractions showed
that expression of exogenous calpastatin was over 5-fold
greater than the endogenous level (Figure 2B). Despite this
increase, the axons exhibited indistinguishable morphology
compared to GFP-expressing axons (Figure 2C). In addition,
there was no detectable change in the axonal level of calpain-1,
calpain-2, or their common small subunit (Figure 2B). Following
axotomy, the majority of control GFP-expressing axons degen-
erated by 8 hr (Figures 2C and 2D). Indeed, the increase in cal-
pastatin significantly delayed the degeneration, i.e., over 70%
of axotomized axons remained intact after 8 hr, compared to
less than 25% in controls (Figures 2C and 2D). Moreover,
although most of the calpastatin-overexpressing axons showed
blebbing signs 16 hr postaxotomy, their morphological continu-
ity was still maintained, which contrasted sharply with the com-
plete fragmentation of control axons. Consistent with this, the
integrity of neurofilaments in calpastatin-overexpressing axons
was also significantly protected over a more extended time
course (Figure 2E). Prior studies have demonstrated an exquisite
inhibitory specificity to calpastatin (Goll et al., 2003), but to
confirm that this observed protection of axons by calpastatin
relied on its inhibition of calpains, we examined the effect
of calpain inhibitor-III on calpastatin-overexpressing axons.
Treatment of control axons with calpain inhibitor-III delayed
degeneration following injury, though to a weaker extent than
with calpastatin overexpression. Importantly, there was no addi-
tive protection when calpain inhibitor-III was added to calpasta-
tin-overexpressing axons (Figures 2C and 2D), supporting the
model that calpastatin functions as a critical regulator of axonal
survival following injury through its inhibition of calpains.
It is interesting to note that, although exogenously expressed
calpastatin preserved axonal survival, the protein itself was
continuously proteolyzed with the same time course as the
endogenous protein (Figure 2E). This is consistent with the
model that as a suicide inhibitor, calpastatin suppresses full-
scale activity of calpains downstream of the signal leading to
initial activation of the proteases. The destruction of exoge-
nously expressed calpastatin might explain the residual cleav-
age of a-internexin / NF-66 seen in calpastatin-overexpressingFigure 3. Calpastatin Regulates Caspase-Dependent Axon Degenerat
(A) Depletion of axonal calpastatin correlates with caspase-3 activation during NG
NGF-neutralizing antibody. One microgram of axonal protein harvested at the in
17-kDa large fragment of cleaved caspase-3.
(B) Caspase-3-dependent calpastatin depletion in NGF-deprived axons; 0.5 mg o
the indicated time points was subjected to immunoblot analysis.
(C) Direct proteolysis of calpastatin protein by active caspase-3; 250 ng calpasta
for 30 min, and then subjected to immunoblot analysis.
(D) Endogenous calpastatin was not required for axonal survival under physiologi
scrambled-shRNA or calpastatin-shRNA was subjected to immunoblot analysis.
(E and F) Knockdown of endogenous calpastatin accelerates axon degeneration
the indicated time points are shown (E). The percentage of degenerated axons w
(G and H) Increase of axonal calpastatin inhibits the degeneration of NGF-dep
expressing axons at the indicated time points are shown (G). The percentage of
(I and J) Calpastatin functions downstream of caspase-3 to regulate the axonal s
DRG neurons at the indicated time points following NGF deprivation was subje
caspase-3, and arrowhead denotes the 115-kDa fragment of aII-spectrin release
See also Figure S2.
Naxons at time points when axons were still largely intact; alterna-
tively, the small fraction of neurons not transduced by the lenti-
viral construct might also account for this.
Calpastatin Regulates Degeneration of Trophic-Factor
Deprived Axons
Axon degeneration occurs not only in pathological conditions,
but also as part of normal neural development. Therefore, we
explored the possibility that the calpastatin-calpain system
might be involved in developmental axon degeneration. As an
in vitro model of developmental pruning, axons of embryonic
DRG neurons undergo caspase-dependent degeneration upon
acute deprivation of NGF (Nikolaev et al., 2009; Vohra et al.,
2010). Interestingly, rapid depletion of axonal calpastatin was
observed with the same time course as that of axon degenera-
tion (Figure 3A). Moreover, calpastatin degradation temporally
correlated with activation, 9–12 hr after NGF-deprivation, of ca-
pase-3 (Figure 3A), a key effector of axon degeneration in this
in vitro paradigm (Simon et al., 2012). To test whether depletion
of calpastatin was downstream of caspase-3 activation, axonal
calpastatin was examined in caspase-3/ DRG neurons, which
are completely resistant to degeneration upon NGF withdrawal
in this assay (Simon et al., 2012). Strikingly, while the protein
was largely degraded around 12 hr in NGF-deprived caspase-
3+/ axons, its level remained unchanged in caspase-3/ axons
for at least 24 hr, the latest time examined (Figure 3B). Of note,
the starting level of axonal calpastatin was not altered in
caspase-3/ axons compared to caspase-3+/ axons.
Previous studies have revealed that calpastatin can be a sub-
strate of active caspase-3 (Kato et al., 2000; Neumar et al., 2003;
Po¨rn-Ares et al., 1998; Wang et al., 1998a). Consistent with this,
we found in the biochemical assay that calpastatin protein can
be directly proteolyzed by active caspase-3 (Figure 3C). On the
other hand, in a cell-free assay for neurofilament fragmentation,
efficient cleavage of axonal neurofilament-M, neurofilament-L,
or a-internexin/NF-66 was not observed with active caspase-3,
but was observed with calpain-1 or calpain-2, which generated
proteolytic patterns resembling those seen in the degenerating
axons after axotomy (Figure S2A). Further, the cleavage of these
neurofilament components also occurred in NGF-deprivedion during Trophic-Factor Deprivation
F deprivation. DRG explants were treated with a final concentration of 50 mg/ml
dicated time points was subjected to immunoblot analysis. Arrow denotes the
f axonal protein harvested from caspase-3+/ or caspase-3/ DRG explants at
tin protein was incubated with increasing amounts of active caspase-3 at 37C
cal conditions; 1 mg of axonal protein harvested from DRG neurons targeted by
upon NGF deprivation. Representative phase-contrast images of the axons at
as quantified (F), mean ± SEM, *p < 0.01.
rived axons. Representative phase-contrast images of GFP- or calpastatin-
degenerated axons was quantified (H), mean ± SEM, *p < 0.01.
urvival; 1 mg of axonal protein harvested from GFP- or calpastatin-expressing
cted to immunoblot analysis. Arrows denote the 17-kDa fragment of cleaved
d by caspase-3 cleavage.
euron 80, 1175–1189, December 4, 2013 ª2013 Elsevier Inc. 1181
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Regulation of Axon Degeneration by Calpastatinwild-type or caspase-3+/ but not caspase-3/ axons (Figures
3A and 3B). Together, these genetic and biochemical data sup-
port a model in which active caspase-3 in NGF-deprived axons
directly cleaves calpastatin, which releases the suppression
of calpains, leading to neurofilament degradation and axon
degeneration.
To determine the role of endogenous calpastatin in regulating
the degeneration of NGF-deprived axons, we transduced DRG
neurons with shRNAs against calpastatin to reduce the endoge-
nous protein to an undetectable level in axons (Figure 3D).
Intriguingly, there was no spontaneous axon degeneration with
this significant reduction of calpastatin level, as assessed by
the phase-contrast images (Figure 3E) or by the integrity of
axonal neurofilament components or nonerythroid a-spectrin
(aII-spectrin; Figure 3D), a known calpain and caspase substrate
(see below). This observation fits with the fact that mice with
genetic ablation of calpastatin are viable, and do not show
detectable signs of spontaneous neurodegeneration in the cen-
tral nervous system (Takano et al., 2005), suggesting that calpas-
tatin is not required for the general viability of axons under
normal physiological conditions. However, when the calpasta-
tin-depleted axons were subjected to NGF deprivation, they un-
derwent accelerated degeneration, i.e., whereas axons targeted
by control scrambled-shRNA were intact at 16 hr following NGF
deprivation, a significant fraction of axons targeted by calpasta-
tin-shRNA had already degenerated at this time point. This ac-
celeration of the degenerative process was also evident at later
time points (Figures 3E and 3F). Conversely, we tested whether
increasing the calpastatin level in axons could prolong their sur-
vival during NGF deprivation. We employed the same strategy to
transduce DRG neurons with the lentivirus expressing calpasta-
tin. In contrast to control GFP-overexpressing axons, which
degenerated around 24 hr after NGF withdrawal, most calpasta-
tin-overexpressing axons remained intact at this time point.
Moreover, a portion of calpastatin-overexpressing axons per-
sisted until 40 hr postdeprivation, a late time point at which con-
trol axons had completely fragmented (Figures 3G and 3H).
Consistent with the preservation of morphological integrity, the
destruction of neurofilaments in calpastatin-overexpressing
axons was also blocked (Figure 3I).
Importantly, activation of caspase-3 was unaffected in
calpastatin-overexpressing axons during NGF deprivation
when compared to control (Figure 3I), further supporting that
calpastatin functions downstream of caspase-3. To rule out
the possibility that in the presence of exogenously expressed
calpastatin, the cleaved caspase-3 might somehow stay inac-
tive, we examined cleavage of axonal aII-spectrin. Calpain-
and caspase-mediated degradation of aII-spectrin both give
rise to fragments around 150 kDa detected by amonoclonal anti-
body (clone AA6), but further cleavage of the 150-kDa fragment
by caspase-3 results in a degradation product of 115 kDa
(Ja¨nicke et al., 1998; Wang et al., 1998b). Consistent with the
involvement of caspase-3 in axon degeneration resulting from
NGF deprivation but not physical injury (Simon et al., 2012), the
appearance of the 115-kDa aII-spectrin fragment was evident
only during the degeneration of NGF-deprived but not axotom-
ized axons (Figure S2B). Importantly, this caspase-3-specific
cleavage of aII-spectrin was indistinguishable between control1182 Neuron 80, 1175–1189, December 4, 2013 ª2013 Elsevier Inc.GFP- and calpastatin-overexpressing axons upon NGF depriva-
tion (Figure 3J), suggesting that maintaining the calpastatin level
can preserve axonal survival even when caspase-3 is function-
ally activated. Together, the results demonstrate that calpastatin
regulates axon degeneration downstream of the NGF depriva-
tion-induced caspase cascade.
Calpastatin Is Broadly Expressed in the Nervous
Systems
To begin to examine the function of calpastatin in regulating axon
degeneration in vivo, we studied the expression pattern of
calpastatin in the nervous systems. We first carried out in situ
hybridization (ISH) to probe expression of calpastatin mRNA in
the mouse central nervous system. CalpastatinmRNA is broadly
detected throughout the adult brain, including cortex and hippo-
campus, and is highly enriched in Purkinje cells in the cerebellum
and in retinal ganglion cells (Figure 4A). Next, we performed
immunohistochemistry (IHC) to determine the expression of cal-
pastatin protein, in combination with several neuronal markers
(NeuN, calbindin, or TUJ1; Figure 4B). Matching our ISH result,
calpastatin protein is expressed in neuronal populations in the
cortex, hippocampus (e.g., pyramidal neurons), cerebellum
(e.g., Purkinje neurons), and retina (e.g., retinal ganglion cells).
In addition, axonal calpastatin was revealed by IHC in the optic
nerve and sciatic nerve (Figure 5A and Figure S4A). Finally, we
examined expression of calpastatin in the developing brain.
ISH showed that calpastatin mRNA is expressed across the
developing brain at postnatal day 1 (Figure S3A), with higher
levels in several regions including the cortex, the pontine forma-
tion, the facial motor nucleus, and the inferior olive. Consistent
with this, calpastatin protein is expressed in the brain through
developmental stages from E16 to P30 as assessed by immuno-
blot (Figure 4C). Interestingly, we observed a shift of calpastatin
during development from a larger to a small isoform, which are
thought to derive from transcripts with different initiation sites
(Goll et al., 2003). Together, these results demonstrate that cal-
pastatin is broadly expressed in the central and peripheral
nervous systems, both during development and in adulthood,
supporting a role for calpastatin in regulating axonal survival in
different contexts.
Calpastatin Regulates Wallerian Degeneration In Vivo
To test whether endogenous calpastatin plays a regulatory role
in Wallerian degeneration in vivo, we examined the protein level
in axons following nerve transection. Resembling our observa-
tions in vitro, there was a dramatic decrease of the calpastatin
level in RGC axons following optic nerve injury (Figures 5A and
5B), which correlated temporally with the degeneration process
(Figures 5D and 5E). Depletion of axonal calpastatin also
occurred following sciatic nerve transection (Figures S4A and
S4B). Interestingly, we noticed that there was a significant in-
crease of calpastatin-expressing nonneuronal cells in the sciatic
nerve after transection, which may represent infiltrating macro-
phages (Figure S4A and data not shown). In fact, presumably
because of these nonneuronal cells, there was actually an in-
crease of calpastatin in the total protein prepared from sciatic
nerves undergoing Wallerian degeneration (Figure S4C). This
result is in line with a previous study showing that there was no
Figure 4. Calpastatin Is Broadly Expressed in the Nervous System
(A and B) Calpastatin is broadly expressed in the nervous system. In situ hybridization (A) and immunohistochemistry (B) were carried out on sagittal sections of
brain and retina from 8-week-old mice. DG, dentate gyrus; GCL, ganglion cell layer; INL, inner nuclear layer; ONL, outer nuclear layer.
(C) Expression of calpastatin in the developing brain; 20 mg of total protein prepared frommouse brains at the indicated developmental stages were subjected to
immunoblot analysis.
See also Figure S3.
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points after injury (Glass et al., 2002), but emphasizes the impor-
tance of examining the protein level specifically in axons.NTo determine the function of endogenous calpastatin in Wal-
lerian degeneration, we constructed adeno-associated virus
(AAV2) expressing shRNAs against calpastatin together with aeuron 80, 1175–1189, December 4, 2013 ª2013 Elsevier Inc. 1183
Figure 5. Calpastatin Regulates Wallerian Degeneration In Vivo
(A andB)Depletionof axonal calpastatin in the transectedopticnerve.Optic nerve transectionwasperformed,andaxonal calpastatin in thenerveswasexaminedby
immunohistochemistryat the indicated timepointsafter injury (A). Thenumberof calpastatin-positive axonswasquantified (B), n=3 for each timepoint,mean±SEM
(legend continued on next page)
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Regulation of Axon Degeneration by CalpastatinTdTomato fluorescent marker (Figure 5C and Figure S4D). We
sparsely transduced RGCs via intravitreal injection of these
AAV2 vectors, which enabled us to directly image TdTomato-
labeled RGC axons in the optic nerve (see Experimental Proce-
dures). Following optic nerve transection, RGC axons targeted
by control scrambled-shRNA remained intact at 24 hr, and a
fraction of axons then started to degenerate at 48 hr, with the
majority fragmented at 72 hr after injury. Consistent with our
in vitro observations, shRNA-knockdown of endogenous
calpastatin did not result in spontaneous degeneration of RGC
axons (Figure 5D), again indicating that calpastatin is dis-
pensable for general viability of axons. However, RGC axons
targeted by calpastatin-shRNAs showed a significant accelera-
tion of Wallerian degeneration after optic nerve transection,
as the number of degenerated axons at 48 hr was almost
double that seen with control scrambled-shRNA, and the
degeneration process was almost complete by 72 hr (Figures
5D and 5E).
Conversely, we examined the effect of calpastatin overex-
pression on the degeneration of injured RGC axons. Intravitreal
delivery of AAV2 vector expressing mouse calpastatin-HA
transduced 70 to 80 percent of total RGCs in the retina, as esti-
mated by colocalization of HA-staining either with TUJ1-positive
RGCs in retinal cryosections (Figure S4E, upper panels) or with
Brn3-positive cells in the whole-mount retina preparation (Fig-
ure S4E, lower panels). GFP-expressing AAV2 achieved a
similar transduction rate of RGCs (data not shown). Without
injury, GFP- and calpastatin-HA-expressing RGC axons
appeared to possess normal myelination and axonal cytoskel-
eton, as assessed by electron microscopy (Figure 5F). Three
days after optic nerve transection, most GFP-expressing axons
had undergone demyelination and destruction of their cytoskel-
eton (Figures 5F and 5G), consistent with that observed with our
TdTomato-labeling approach (Figure 5E). After 6 days, a com-
plete breakdown of axonal structures was observed across
the entire nerves (Figures 5F and 5G). In contrast, there was a
significant protection of calpastatin-expressing RGC axons
against Wallerian degeneration: over 50% of the axons retained
a tightly packed myelin-sheath and intact cytoskeleton 3 days
after injury, and some axons still appeared intact at 6 days post-
transection (Figures 5F and 5G). In parallel, we carried out
immunoblot analysis of the protein extracts from transected
nerves, and expression of calpastatin-HA significantly protected
neurofilament components after injury (Figure S4F). We also
observed a depletion of exogenously expressed calpastatin-
HA in transected nerves (Figure S4F), resembling our in vitro
results (Figure 2E). Together, these results support the idea
that the calpastatin cell autonomously regulates Wallerian
degeneration in vivo.(C–E) Knockdown of endogenous calpastatin in RGC axons accelerated the dege
out as described in the Experimental Procedures. Design of AAV2-shRNA vectors
projection images of TdTomato-labeled RGC axons at the indicated time point
quantified (E), n = 4 per condition for each time point, mean ± SEM, *p < 0.01.
(F and G) Increase of calpastatin level in RGC axons inhibited Wallerian degenerat
(HA)-tagged calpastatin. Representative electron-microscope images of RGC ax
of degenerated axons was quantified (G), n = 4 per condition for each time point
See also Figure S4.
NCalpastatin Functions Downstream of Caspases in
Developmental Pruning
Finally, we explored the function of calpastatin in developmental
degeneration of axons in vivo. The stereotyped pruning of devel-
oping RGC axons in the superior colliculus was chosen as the
model system because it has been shown to occur via local
degeneration (Feldheim and O’Leary, 2010; Hoopfer et al.,
2006). Moreover, our recent studies have demonstrated that
this degeneration process involves the same caspase cascade
that operates in the degeneration of NGF-deprived sensory
axons (Simon et al., 2012). We employed an in utero electropo-
ration approach to target RGCs at E13 and then examine their
labeled axons in the superior colliculus at indicated postnatal
days (see Experimental Procedures); this approach yields equiv-
alent results to the more classic DiI-labeling method (Simon
et al., 2012). First, we determined the function of endogenous
calpastatin in the pruning by electroporating control scram-
bled-shRNA or calpastatin-shRNA plasmids into the RGCs of
wild-type mice. Because RGC axons are normally pruned back
between postnatal day 1 to day 7 (P1–P7; Feldheim andO’Leary,
2010; Simon et al., 2012), the mice were examined at P3 when
the pruning is in process. Strikingly, while there was still a large
number of axons present in the extreme posterior edge of the
colliculus (posterior superior colliculus [PSC]; Figure 6A) in
control scrambled-shRNA condition, the vast majority of axons
targeted by calpastatin-shRNA had already been pruned back
(Figures 6B and 6C). Thus, the endogenous calpastatin cell
autonomously regulates developmental axon degeneration
in vivo. Next, we tested whether overexpression of calpastatin
could inhibit pruning of RGC axons by examining GFP- or cal-
pastatin-electroporated wild-type mice at P6, when the normal
pruning process should have been largely completed. We
observed 3-foldmore axons in the PSC of calpastatin-electropo-
rated animals compared to GFP-electroporated controls (Fig-
ures 6D and 6E), showing that increasing the calpastatin level
delays axon pruning in vivo. Of note, expression of GFP or cal-
pastatin did not affect the initial overshooting of RGC axons
past the future termination zone on the superior colliculus at
P1 (Figure S5A).
Our results with the in vitro model of NGF deprivation have
shown that caspase-3 activation functions upstream of calpas-
tatin in axon degeneration. In fact, a similar delay of RGC axons
pruning has also been reported in caspase-3/ mice (Simon
et al., 2012). We therefore set out to determine the genetic
interaction of caspase-3 and calpastatin in vivo. Neither
shRNA-knockdown of calpastatin (Figures 6F and 6G) nor
overexpression of calpastatin (Figures 6H and 6I) modified the
delayed pruning of RGC axons in caspase-3/ animals, sug-
gesting that calpastatin and caspase-3 function in the sameneration following transection. Intravitreal injection of viral vectors was carried
for labeling of RGC axons is shown in (C). Representative maximum-intensity-
s posttransection are shown (D). The percentage of degenerated axons was
ion. RGCs were transduced by AAV2 vectors expressing GFP or hemagglutinin
ons at the indicated time points posttransection are shown (F). The percentage
, mean ± SEM, *p < 0.01.
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Figure 6. Calpastatin Regulates the Developmental Pruning of RGC Axons Downstream of Caspase-3
In utero electroporation of RGCs in E13.5 mouse embryos, and the imaging of superior colliculus at the indicated postnatal days were carried out as described in
the Experimental Procedures.
(A) Diagram of mouse superior colliculus (SC). A, anterior; P, posterior; M, medial; L, lateral; and TZ, termination zone. The PSC is defined as the region within
100 mm of the posterior edge of the SC.
(B and C) Knockdown of endogenous calpastatin accelerated the pruning of RGC axons. Representative maximum-intensity-projection images of DsRed-
positive axons within the SC of scrambled-shRNA or calpastatin-shRNA-electroporated mice at postnatal day 3 (P3) are shown (B). The number of DsRed-
positive axons in the PSC regions was quantified (C), n = 7 for scrambled-shRNA and n = 4 for calpastatin-shRNA.
(D and E) Increasing the calpastatin level delayed the pruning of RGC axons. Representative maximum-intensity-projection images of DsRed-positive axons
within the SC of GFP- or calpastatin-electroporated mice at P6 are shown (D). The number of DsRed-positive axons in the PSC was quantified (E), n = 5 for GFP
and n = 13 for calpastatin.
(legend continued on next page)
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axons. These results further support that calpastatin functions
downstream of caspase-3 to regulate developmental axon
degeneration in vivo.DISCUSSION
In this study, we provide evidence identifying endogenous cal-
pastatin as a key regulator of axonal survival in both injury-
induced and developmental degeneration. Our results suggest
that destruction of endogenous calpastatin in injured axons re-
leases its inhibitory action on calpains, leading to full-scale cal-
pain activation and the demise of axons. Conversely, increasing
the axonal level of calpastatin via viral delivery inhibited degener-
ation in neuronal cultures as well as in vivo, consistent with the
protection recently reported in calpastatin transgenicmice in vivo
(Ma et al., 2013). Unexpectedly, this calpastatin-calpain regula-
tory module also functions in models of developmental axonal
death involving the classic apoptotic pathway, with depletion
of endogenous calpastatin downstream of caspase activation
required for degeneration. The fact that axons can be rescued
by maintaining the calpastatin level without affecting upstream
caspase activation implies that caspases are a trigger of the
degenerative signal rather than direct executioners of axons.
This might reflect the relatively stringent specificity of caspases,
which renders the proteases inefficient at degrading axonal
components such as neurofilaments (Posmantur et al., 1998;
Figure S2A), an event required to dismantle axons. Instead,
proteolysis of calpastatin by active caspase-3 releases inhibition
of calpains, which are potent proteases with more promiscuous
substrate specificity (Goll et al., 2003), ensuring a timely
elimination of unwanted axons during development. This
possibility is supported by our finding that the pruning of RGC
axons in the superior colliculus is critically regulated by the cal-
pastatin level (Figure 6). Because we observed that calpastatin
is broadly expressed in the developing brain, it might function
in regulating other instances of developmental axon degenera-
tion as well.
We also found that the previously reported involvement of the
proteasome inWallerian degeneration (MacInnis and Campenot,
2005; Zhai et al., 2003) is neuronal-type dependent. In fact,
among the four neuronal types tested, only the axotomized
axons of SCG neurons could be protected by specific inhibitors
of the proteasome. What the unique component(s) in SCG axons
is that confers this proteasome-dependence remains to be eluci-
dated. Intriguingly, while inhibition of the proteasome had little
effect on physically injured axons of DRG neurons, it significantly
blocked axonal death upon NGF deprivation by delaying cas-
pase-3 activation (Figures S2C and S2D). Together with previous(F and G) Knockdown of endogenous calpastatin did not alter the delayed prun
projection images of DsRed-positive axons within the SC of scrambled-shRNA or
number of DsRed-positive axons in the PSC was quantified (E), n = 11 for scram
(H and I) Increasing the calpastatin level had no additive effect on the delayed pru
projection images of DsRed-positive axons within the SC of GFP- or calpastatin-
positive axons in the PSC regions was quantified (I), n = 4 for GFP and n = 5 for ca
with higher magnification. All the values are presented as mean ± SEM, *p < 0.0
See also Figure S5.
Nstudies in Drosophila (Watts et al., 2003), these results suggest a
more conserved role of the proteasome in the regulation of
developmental pruning, with a hierarchy of protease actions,
i.e., the proteasome most upstream, caspases further down-
stream, and calpains further yet.
The activity of calpains depends on high concentrations of
Ca2+, and depletion of endogenous calpastatin alone is not
sufficient to cause axon degeneration in vitro or in vivo (Figures
3D and 5D). We therefore infer that, besides proteolyzing
calpastatin, caspases need to activate additional downstream
pathway(s) to increase cytosolic Ca2+. Different mechanisms
for Ca2+ influx or loss of intracellular Ca2+ homeostasis have
been proposed to underlie axon degeneration. Those mecha-
nisms—including direct Ca2+ influx through the damaged
plasma membrane (Schlaepfer, 1974), activation of voltage-
gated Ca2+ channels (George et al., 1995), reverse operation
of Na+/Ca2+ exchangers (LoPachin and Lehning, 1997), or
opening of the mitochondrial permeability transition pore (Bar-
rientos et al., 2011)—are not mutually exclusive. Depending
on neuronal type as well as degenerative insult, one or more
mechanism(s) could make a prominent contribution. In fact,
we found that degeneration of embryonic DRG axons induced
by either injury or NGF deprivation could both be inhibited by
amiloride (Figure S2E), suggesting a role for Ca2+ influx via ami-
loride-sensitive ion channel(s) at least in these in vitro models.
Regardless of the source of Ca2+ that activates calpains, our
results highlight that calpastatin is a key checkpoint for axonal
survival onto which multiple degenerative pathways converge
(Figure S5B).
It will be of interest to determine whether calpastatin can exert
a protective function in axons during the progression of neurode-
generative disorders besides traumatic injury, especially those
with documented axonal dysfunction or damage. In fact, a signif-
icant reduction of calpastatin has been reported along dendrites
of pyramidal neurons in the cortices of Alzheimer’s disease
patients (Rao et al., 2008). Whether the protein undergoes a
similar change in the axonal/neurite compartments in other
disease conditions requires further detailed examination. Mean-
while, sustaining the level of calpastatin via viral vectors, or
delivering its derivative peptides, might be of therapeutic benefit
in treating such neurodegenerative disorders. The approach of
blocking the detrimental activity of calpains using their natural
inhibitor could complement approaches based on conventional
small-molecule inhibitors that, in the case of calpains, so far
lack great specificity.
EXPERIMENTAL PROCEDURES
Antibodies, AAV2 preparation, and other information can be found in the Sup-
plemental Experimental Procedures.ing of RGC axons in caspase-3/ mice. Representative maximum-intensity-
calpastatin-shRNA-electroporated caspase-3/mice at P6 are shown (F). The
bled-shRNA and n = 7 for calpastatin-shRNA.
ning of RGC axons in caspase-3/mice. Representative maximum-intensity-
electroporated caspase-3/ mice at P6 are shown (H). The number of DsRed-
lpastatin. Dashed boxes in (B), (D), (F), and (H) indicate the PSC regions shown
1, n.s., not significant. Scale bar, 100 mm.
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All surgical procedures in mice were performed in compliance with the proto-
cols approved by the IACUC of Genentech and the Rockefeller University.
Intravitreal injection of AAV2 expressing calpastatin-HA or shRNAs against
calpastatin was performed on 8- to 10-week-oldmice. The animals were anes-
thetized, and a customized 33G 30-beveled needle (Hamilton) attached to the
Hamilton syringe was passed through the sclera into the vitreous. For overex-
pression of calpastatin-HA or GFP, 13 107 transduction units of AAV2 vectors
were delivered, which transduced over 70% of total RGCs in the retina. For
shRNA-knockdown, 5 3 103 transduction units of AAV2-shRNA vectors
were delivered, which transduced approximately 500 to 1,000 RGCs in the
retina. Three to four weeks after the viral injection, the animals were anesthe-
tized, and the left optic nerves were completely transected via enucleation.
At indicated time points after transection, the nerve samples were pro-
cessed either for immunohistochemistry or biochemical analysis as described
in the Supplemental Experimental Procedures. To visualize TdTomato-labeled
RGC axons, mice were transcardially perfused with ice-cold 4% paraformal-
dehyde/10% (w/v) sucrose/PBS. The optic nerves were postfixed in 4% para-
formaldehyde / PBS overnight. After washing three times in PBS, the nerves
were transferred into 30% sucrose/PBS at 4C overnight. The segment of
nerves about 2 mm proximal to the optic chiasm were imaged by confocal
microscope, and 100–150 axons in each nerve sample were examined, with
any sign of blebbing or fragmentation scored as degeneration. The p value
was calculated by an unpaired two-tailed t test.
In Utero Electroporation of Retinal Ganglion Cells
In utero electroporation of RGCswas carried out as previously described (Gar-
cia-Frigola et al., 2007; Simon et al., 2012). C57B/6 timed-pregnant females
were anesthetized at E13. The uterine horns were exposed by an incision
through the abdominal dermis and body wall muscle. The right eye of each
embryowas injected through the uterine wall using a fine glass capillary needle
connected to a pressure injector (Picospritzer, Parker), and 0.5 ml of 1 mg/ml
plasmid mixture (CAGGS promoter-driven calpastatin-IRES-GFP or IRES-
GFP control, mixed with DsRed plasmid at 1:1 molar ratio) was delivered, fol-
lowed by the electroporation by application of a series of five square electrical
pulses (36 V, 50 ms, 450 ms interval) through a pair of 3-mm-diameter paddle
electrodes (Tweezertrode, BTX). The uterine horns were then placed back into
the abdominal cavity, the incision was closed by suture, and the females were
treated with an analgesic prior to recovery from anesthesia. In the whole-
mount retina preparations from the electroporated pups, GFP/DsRed cotrans-
fected RGC populations located primarily in the central region of the retina,
and the cotransfection efficiency was observed to be >90% across the
experiments.
To examine the developmental pruning of RGC axons in the superior collicu-
lus, the electroporated pups were transcardially perfused with ice-cold 4%
paraformaldehyde/10% (w/v) sucrose/PBS at indicated developmental ages.
After postfixation overnight in 4% paraformaldehyde/PBS, each brain sample
was immersed in PBS and stereotactically positioned under an objective lens
(103 NA 0.6, Olympus). A volume of 1.0 3 1.0 3 0.4 mm of the left superior
colliculus was imaged en bloc by two-photon laser scanning microscopy with
1,020 nm pulsed laser (Mai Tai DeepSee laser, Spectra Physics) and 620/
60 nm bandpass filter (Chroma), at a resolution 1.1 mm / pixel (Ultima IV, Prairie
Technologies). The extent of axon pruning was determined by counting the
number of DsRed-expressing axons within 100 mm of the posterior edge of
the superior colliculus. The p value was calculated by an unpaired two-tailed
t test.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and five figures and can be found with this article online at http://dx.doi.org/
10.1016/j.neuron.2013.08.034.
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